MicroStockProfit.com releases investment report featuring Rexahn Pharmaceuticals

Jun 3 2010

MicroStockProfit.com announces an investment report featuring Rexahn Pharmaceuticals Inc. (AMEX:RNN). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/lp/RNN

Rexahn Pharmaceuticals Inc. (RNN) is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of treatments for cancer, central nervous system (CNS) disorders, sexual dysfunction and other medical needs. The Company develops therapies that make it possible to regain normalcy for patients suffering from disease. It has three drug candidates in Phase II clinical trials during the year ended December 31, 2008, and six or more other drug candidates in pre-clinical development. The Company's clinical-stage pipeline products include Archexin, an anti-cancer Akt inhibitor; Serdaxin, an antidepressant and CNS Disorders drug; and Zoraxel, an erectile dysfunction (ED) and sexual dysfunction drug. RNN's pre-clinical pipeline includes RX-0201-Nano, RX-0047-Nano, Nano-polymer Anticancer Drugs, RX-0183, RX-5902 and RX-3117. 

Message Board Search for RNN: http://www.boardcentral.com/boards/RNN

In the report, the analyst notes:

"For the three-month period ended March 31, 2010, RNN recorded revenues of $18,750.  RNN recorded the same amounts in the same period of 2009.  In all periods, the revenue reflects the recognition of deferred revenue from a collaborative research agreement with Rexgene Biotech Co. Ltd., a minority stockholder.  

"RNN recently announced that it will initiate a phase IIb clinical trial for ZoraxelTM in the treatment of erectile dysfunction (ED). The phase IIb study is designed to assess Zoraxel's efficacy in approximately 225 male subjects, ages 18 to 65, with ED. The double blind, randomized, placebo-controlled, 12-week study will include the International Index of Erectile Function (IIEF), Sexual Encounter Profile (SEP) survey and quality of life study endpoints."